Beta-blockade is not associated with improved outcomes in isolated severe extracranial injury: an observational cohort study.


Journal

Scandinavian journal of trauma, resuscitation and emergency medicine
ISSN: 1757-7241
Titre abrégé: Scand J Trauma Resusc Emerg Med
Pays: England
ID NLM: 101477511

Informations de publication

Date de publication:
08 Sep 2021
Historique:
received: 21 02 2021
accepted: 30 08 2021
entrez: 9 9 2021
pubmed: 10 9 2021
medline: 11 9 2021
Statut: epublish

Résumé

There is evidence supporting the use of beta-blockade in patients with traumatic brain injury. The reduction in sympathetic drive is thought to underlie the relationship between beta-blockade and increased survival. There is little evidence for similar effects in extracranial injuries. This study aimed to assess the association between beta-blockade and survival in patients suffering isolated severe extracranial injuries. Patients treated at an academic urban trauma centre during a 5-year period were retrospectively identified. Adults suffering isolated severe extracranial injury [Injury Severity Score (ISS) ≥ 16 with Abbreviated Injury Score of ≤ 2 for any intracranial injury] were included. Patient characteristics and outcomes were collected from the trauma registry and hospital medical records. Patients were subdivided into beta-blocker exposed and unexposed groups. Patients were matched using propensity score matching. Differences were assessed using McNemar's or paired Student's t test. The primary outcome of interest was 90-day mortality and secondary outcome was in-hospital complications. 698 patients were included of whom 10.5% were on a beta-blocker. Most patients suffered blunt force trauma (88.5%) with a mean [standard deviation] ISS of 24.6 [10.6]. Unadjusted mortality was higher in patients receiving beta-blockers (34.2% vs. 9.1%, p < 0.001) as were cardiac complications (8.2% vs. 1.4%, p = 0.002). Patients on beta-blockers were significantly older (69.5 [14.1] vs. 43.2 [18.0] years) and of higher comorbidity. After matching, no statistically significant differences were seen in 90-day mortality (34.2% vs. 30.1%, p = 0.690) or in-hospital complications. Beta-blocker therapy does not appear to be associated with improved survival in patients with isolated severe extracranial injuries.

Sections du résumé

BACKGROUND BACKGROUND
There is evidence supporting the use of beta-blockade in patients with traumatic brain injury. The reduction in sympathetic drive is thought to underlie the relationship between beta-blockade and increased survival. There is little evidence for similar effects in extracranial injuries. This study aimed to assess the association between beta-blockade and survival in patients suffering isolated severe extracranial injuries.
METHODS METHODS
Patients treated at an academic urban trauma centre during a 5-year period were retrospectively identified. Adults suffering isolated severe extracranial injury [Injury Severity Score (ISS) ≥ 16 with Abbreviated Injury Score of ≤ 2 for any intracranial injury] were included. Patient characteristics and outcomes were collected from the trauma registry and hospital medical records. Patients were subdivided into beta-blocker exposed and unexposed groups. Patients were matched using propensity score matching. Differences were assessed using McNemar's or paired Student's t test. The primary outcome of interest was 90-day mortality and secondary outcome was in-hospital complications.
RESULTS RESULTS
698 patients were included of whom 10.5% were on a beta-blocker. Most patients suffered blunt force trauma (88.5%) with a mean [standard deviation] ISS of 24.6 [10.6]. Unadjusted mortality was higher in patients receiving beta-blockers (34.2% vs. 9.1%, p < 0.001) as were cardiac complications (8.2% vs. 1.4%, p = 0.002). Patients on beta-blockers were significantly older (69.5 [14.1] vs. 43.2 [18.0] years) and of higher comorbidity. After matching, no statistically significant differences were seen in 90-day mortality (34.2% vs. 30.1%, p = 0.690) or in-hospital complications.
CONCLUSIONS CONCLUSIONS
Beta-blocker therapy does not appear to be associated with improved survival in patients with isolated severe extracranial injuries.

Identifiants

pubmed: 34496923
doi: 10.1186/s13049-021-00947-6
pii: 10.1186/s13049-021-00947-6
pmc: PMC8425052
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

132

Informations de copyright

© 2021. The Author(s).

Références

J Emerg Trauma Shock. 2014 Oct;7(4):305-9
pubmed: 25400393
Am Surg. 2008 Sep;74(9):866-72
pubmed: 18807680
J Trauma. 2007 Jan;62(1):56-61; discussion 61-2
pubmed: 17215733
J Trauma. 2008 Nov;65(5):1016-20
pubmed: 19001968
J Trauma. 2010 Oct;69(4):776-82
pubmed: 20938265
Intensive Care Med. 1994;20(4):260-7
pubmed: 8046119
J Trauma Acute Care Surg. 2014 Feb;76(2):504-9; discussion 509
pubmed: 24458058
Surgery. 2009 Feb;145(2):235-42
pubmed: 19167980
Br J Anaesth. 2000 Jul;85(1):109-17
pubmed: 10927999
BJS Open. 2018 Jun 23;2(6):392-399
pubmed: 30511040
Anesthesiology. 1998 Jan;88(1):7-17
pubmed: 9447850
Nature. 1975 Dec 4;258(5534):437-40
pubmed: 620
J Am Coll Surg. 2008 Mar;206(3):432-8
pubmed: 18308212
J Trauma. 2009 Jan;66(1):154-9; discussion 159-61
pubmed: 19131818
Crit Care Med. 1998 Nov;26(11):1881-6
pubmed: 9824083
J Trauma. 2008 Jan;64(1):46-52
pubmed: 18188098
Crit Care. 2017 Feb 9;21(1):25
pubmed: 28179016
Innate Immun. 2008 Dec;14(6):333-44
pubmed: 19039057
J Trauma Acute Care Surg. 2014 Mar;76(3):804-8
pubmed: 24553552
Crit Care Med. 2005 Mar;33(3):654-60
pubmed: 15753760
N Engl J Med. 1996 Dec 5;335(23):1713-20
pubmed: 8929262
Am J Surg. 2012 Nov;204(5):697-703
pubmed: 22578406
Am Surg. 2016 Jul;82(7):575-9
pubmed: 27457854
J Trauma. 2010 Sep;69(3):645-52
pubmed: 20526211
J Trauma. 2007 Jan;62(1):26-33; discussion 33-5
pubmed: 17215730
Int J Cardiol. 2005 Nov 2;105(2):141-6
pubmed: 16243104
Nat Med. 1998 Jul;4(7):808-13
pubmed: 9662372
World J Surg. 2015 Aug;39(8):2076-83
pubmed: 25809062
Am J Physiol. 1958 Sep;194(3):590-6
pubmed: 13571432
Eur J Pharmacol. 1998 Mar 5;344(2-3):251-9
pubmed: 9600661
J Trauma Acute Care Surg. 2012 Feb;72(2):428-36
pubmed: 22439205
Am J Physiol. 1976 Aug;231(2):489-94
pubmed: 961902

Auteurs

Lin Sadi (L)

Department of Surgery, Capio St Görans Hospital, Stockholm, Sweden.

Gabriel Sjölin (G)

Department of Surgery, Örebro University Hospital, Örebro, Sweden.
School of Medical Sciences, Örebro University, Örebro, Sweden.

Rebecka Ahl Hulme (R)

School of Medical Sciences, Örebro University, Örebro, Sweden. rebecka.ahl-hulme@sll.se.
Division of Trauma and Emergency Surgery, Department of Surgery, Karolinska University Hospital, Stockholm, Sweden. rebecka.ahl-hulme@sll.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH